Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Denali Therapeutics $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Haleon $3 billion secondary placing of ordinary shares
The private placement included 700,000,000 ordinary shares
AbbVie $4 billion senior notes offering
The investment-grade notes are due 2028, 2030, 2035 and 2055
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
NeuroPace $74.75 million follow-on offering
The stock is listed on the Nasdaq Global Market
Oculis Holding $100 million follow-on equity offering
The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market
BioVersys CHF 80 million IPO and concurrent private placement
We advised AMR Action Fund on its investment in BioVersys
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065